FTDI
NBIX icon

First Trust Direct Indexing’s Neurocrine Biosciences NBIX Stock Holding History

First Trust Direct Indexing’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,708
Closed -$542K – 589
2024
Q3 		$542K Buy
4,708
+264
+6% +$36.2K 0.03% 519
2024
Q2 		$612K Buy
4,444
+314
+8% +$43.1K 0.04% 449
2024
Q1 		$570K Buy
4,130
+933
+29% +$127K 0.04% 439
2023
Q4 		$421K Buy
3,197
+1,017
+47% +$117K 0.04% 489
2023
Q3 		$245K Buy
+2,180
New +$230K 0.03% 579
2023
Q1 		– Sell
-1,867
Closed -$223K – 713
2022
Q4 		$223K Buy
+1,867
New +$219K 0.03% 592
2021
Q1 		– Sell
-942
Closed -$90K – 766
2020
Q4 		$90K Buy
+942
New +$91K 0.02% 546

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Trust Direct Indexing's NBIX Position: Q4 2024 in Review

First Trust Direct Indexing sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 4,708 shares — an estimated $542K sold.

First Trust Direct Indexing first reported a position in NBIX in Q4 2020 and held it in 7 quarters. The position peaked at $612K in Q2 2024. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • First Trust Direct Indexing reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • First Trust Direct Indexing sold 4,708 Neurocrine Biosciences shares in Q4 2024, an estimated $542K.
  • First Trust Direct Indexing first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 7 quarters.
  • First Trust Direct Indexing's Neurocrine Biosciences position peaked at $612K in Q2 2024.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on First Trust Direct Indexing's 13F filing for Q4 2024.